A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia
Latest Information Update: 07 Apr 2022
Price :
$35 *
At a glance
- Drugs Evolocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Acronyms PROFICIO; RUTHERFORD-2
- Sponsors Amgen
- 17 Aug 2018 Results (n=3146) of pooled analysis of this and other three trials (LAPLACE-2, MENDEL-2, GAUSS-2) published in the Clinical Cardiology.
- 01 Mar 2017 Results (n=6026) of pooled safety analysis of this and other eleven trials (LAPLACE-TIMI 57,RUTHERFORD,GAUSS,MENDEL,YUKAWA,LAPLACE-2,RUTHERFORD-2,GAUSS-2,MENDEL-2,DISCARTES,THOMAS-1,THOMAS-2) published in the Circulation.
- 02 Nov 2016 Post-hoc analysis presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.